Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 1:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 243 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer Clear all
Terminated Phase 2 Interventional

Randomized Safety, Tolerability and Pilot Efficacy of AN-1792 in Alzheimer's Disease

NCT00021723
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
AN-1792 also known as AIP-001
Biological
Lead sponsor
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Industry
Eligibility
50 Years to 85 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
11
States / cities
Peoria, Arizona • Phoenix, Arizona • Beverly Hills, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2009 · Synced Oct 8, 2026, 1:43 AM EDT
Terminated Phase 2 Interventional Results available

A Study Evaluating Desvenlafaxine Sustained Release (DVS SR) in Adult Female Outpatients With Fibromyalgia

NCT00696787
View directory record Official record
Conditions
Fibromyalgia
Interventions
Desvenlafaxine Sustained Release (DVS SR), Lyrica® (Pregabalin), Placebo
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
27
States / cities
Huntsville, Alabama • Roseville, California • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2013 · Synced Oct 8, 2026, 1:43 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Evaluation of Airway Gene Expression in COPD and Controlled Populations

NCT00571792
View directory record Official record
Conditions
COPD
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
45 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Oct 8, 2026, 1:43 AM EDT
Completed Phase 2 Interventional

Study Evaluating SCA-136 in Subjects With Acute Exacerbations of Schizophrenia

NCT00265551
View directory record Official record
Conditions
Schizophrenia
Interventions
SCA-136 (200 mg), SCA-136 (400 mg), olanzapine (15 mg), placebo
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
35
States / cities
Little Rock, Arkansas • Cerritos, California • Costa Mesa, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2007 · Synced Oct 8, 2026, 1:43 AM EDT
Terminated Phase 1 Interventional

Temsirolimus in Combination With Gemcitabine in Previously Untreated Metastatic Pancreatic Cancer

NCT00593008
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
Temsirolimus, Gemcitabine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 2, 2011 · Synced Oct 8, 2026, 1:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Safety, Tolerability, Pharmacokinetics and Pharmcodynamics of ILV-094 in Healthy Subjects

NCT00447681
View directory record Official record
Conditions
Healthy
Interventions
ILV-094
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 13, 2007 · Synced Oct 8, 2026, 1:43 AM EDT
Completed Phase 2 Interventional

Tigecycline for Treatment of Rapidly Growing Mycobacteria

NCT00600600
View directory record Official record
Conditions
Mycobacterium Abscessus Lung Disease, Rapidly Growing Mycobacterial Lung Disease
Interventions
Tigecycline
Drug
Lead sponsor
The University of Texas Health Science Center at Tyler
Other
Eligibility
10 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Tyler, Texas
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Oct 8, 2026, 1:43 AM EDT
Completed Phase 2 Interventional

Study Evaluating Etanercept in Moderate to Severe Asthma

NCT00141791
View directory record Official record
Conditions
Asthma
Interventions
Etanercept
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
13
States / cities
Birmingham, Alabama • Denver, Colorado • Sarasota, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2009 · Synced Oct 8, 2026, 1:43 AM EDT
Completed Not applicable Interventional

A Safety, Pilot Pharmacokinetics and Neurocognitive Study of AS-101 in Combination With Zidovudine in AIDS/ARC Patients

NCT00002013
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, AS-101
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 8, 2026, 1:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating IMA-638 in Healthy Japanese

NCT00340327
View directory record Official record
Conditions
Healthy
Interventions
IMA-638
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
20 Years to 45 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2007 · Synced Oct 8, 2026, 1:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating The Potential Effect Of Lansoprazole On The Pharmacokinetics Of Bosutinib In Healthy Subjects

NCT00952913
View directory record Official record
Conditions
Healthy
Interventions
Bosutinib, Lansoprazole
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 19, 2011 · Synced Oct 8, 2026, 1:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of 3 New Formulations of Premarin/MPA Compared With Premarin/MPA (Prempro)

NCT00472927
View directory record Official record
Conditions
Postmenopause
Interventions
Premarin/MPA 0.45 mg/1.5 mg
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
35 Years to 70 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 6, 2007 · Synced Oct 8, 2026, 1:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating the Effects of Multiple Oral Doses of ERB-041 on Cardiac Repolarization in Healthy Subjects

NCT00316459
View directory record Official record
Conditions
Healthy, Long QT Syndrome
Interventions
ERB-041
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 13, 2007 · Synced Oct 8, 2026, 1:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Comparing Two Manufacturing Processes for Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg (LNG/EE) in Healthy, Cycling Women

NCT00319163
View directory record Official record
Conditions
Healthy
Interventions
levonorgestrel/ethinyl estradiol
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 7, 2009 · Synced Oct 8, 2026, 1:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating 3 New Formulations of SKI-606 in Healthy Adult Subjects

NCT00499538
View directory record Official record
Conditions
Healthy
Interventions
SKI-606
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 27, 2007 · Synced Oct 8, 2026, 1:43 AM EDT
Completed Phase 2 Interventional

A Study of rhBMP-2/CPM in Closed Fractures of the Humerus

NCT00384852
View directory record Official record
Conditions
Fractures
Interventions
rhBMP-2/CPM
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
9
States / cities
Little Rock, Arkansas • Aurora, Colorado • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2013 · Synced Oct 8, 2026, 1:43 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Study Evaluating Pneumococcal Vaccine in Healthy Infants

NCT00205803
View directory record Official record
Conditions
Healthy Subjects, Pneumococcal Infections
Interventions
13-Valent Pneumococcal Conjugate Vaccine (13vPnC), 7-Valent Pneumococcal Conjugate Vaccine (7vPnC)
Biological
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
42 Days to 98 Days
Enrollment
249 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 15, 2012 · Synced Oct 8, 2026, 1:43 AM EDT
Terminated Phase 1 Interventional Results available

Phase I/II Study of Irinotecan and Temsirolimus in Patients With Refractory Sarcomas

NCT00996346
View directory record Official record
Conditions
Sarcoma
Interventions
Irinotecan&Temsirolimus:Arm1, Level 1, Irinotecan&Temsirolimus:Arm 1, Level 2, Irinotecan&Temsirolimus:Arm 2, Level 1
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
10 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Sep 1, 2015 · Synced Oct 8, 2026, 1:43 AM EDT
Terminated Phase 1 Interventional

Study Evaluating Vaccine in Adults With HIV

NCT00195312
View directory record Official record
Conditions
HIV Infections
Interventions
HIV-1 gag DNA (formulated with bupivacaine), IL-15 DNA (formulated with bupivacaine), IL-12 DNA (formulated with bupivacaine), Sodium chloride injection USP (0.9%)
Biological
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
6
States / cities
Birmingham, Alabama • Denver, Colorado • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2007 · Synced Oct 8, 2026, 1:43 AM EDT
Completed Not applicable Interventional Results available

A Study To Evaluate Methods To Evaluate Back Pain

NCT01045993
View directory record Official record
Conditions
Pain
Interventions
Heat Device, Sham Device, marketed analgesic, Placebo
Device · Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2013 · Synced Oct 8, 2026, 1:43 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Pantoprazole Sodium Enteric-Coated Spheroid Suspension In Infants With Presumed GERD

NCT00259012
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
pantoprazole sodium enteric-coated spheroid suspension
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
1 Month to 11 Months
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
16
States / cities
Little Rock, Arkansas • Loma Linda, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 7, 2010 · Synced Oct 8, 2026, 1:43 AM EDT
Completed Phase 2 Interventional

Study Evaluating Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia After Stem Cell Transplant

NCT00044733
View directory record Official record
Conditions
Acute Myelogenous Leukemia
Interventions
Mylotarg (gemtuzumab ozogamicin) Injection
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
0 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
13
States / cities
Little Rock, Arkansas • Hartford, Connecticut • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated May 18, 2006 · Synced Oct 8, 2026, 1:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Comparing Premarin®/MPA, PREMPRO® and Provera® in Healthy Postmenopausal Women

NCT00543634
View directory record Official record
Conditions
Postmenopause
Interventions
Premarin/MPA, Provera 10 mg
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
35 Years to 70 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 22, 2010 · Synced Oct 8, 2026, 1:43 AM EDT
Terminated Phase 4 Interventional Results available

Tacrolimus to Sirolimus Conversion for Delayed Graft Function

NCT00931255
View directory record Official record
Conditions
Kidney Transplant, Delayed Graft Function
Interventions
Tacrolimus, Sirolimus
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 8, 2026, 1:43 AM EDT